{
  "doi": "10.1056/NEJMoa2515168",
  "pubdate": "2025-12-09",
  "articleID": "NJ202512090000008",
  "landingDoi": "10.1056/NEJMoa2515168",
  "displayType": [
    "Original Article"
  ],
  "volume": "",
  "issue": "",
  "citation": "10.1056/NEJMoa2515168",
  "thumbnail": "",
  "title": "Ianalumab plus Eltrombopag in Immune Thrombocytopenia",
  "duration": null,
  "hasCME": false,
  "hasPoll": false,
  "isArchive": false,
  "isFree": false,
  "hasAudio": false,
  "hasVideo": false,
  "hasInteractive": false,
  "hasVisualAbstract": false,
  "hasPDF": true,
  "stringAuthors": "A. Cuker and Others",
  "relatedContent": [],
  "articleType": [
    "Original Article"
  ],
  "journal": null,
  "articleCategory": [
    "research"
  ],
  "text": "In a phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo.",
  "mediaType": null,
  "mediaTitle": null,
  "relatedObject": [],
  "aboutness": [
    "ianalumab",
    "eltrombopag",
    "Inosine Triphosphate",
    "Purpura, Thrombocytopenic, Idiopathic",
    "9-(1'-hydroxy-2'-(hydroxymethyl)ethoxy)methylguanine",
    "Fatigue",
    "Glucocorticoids",
    "Platelet Count",
    "Treatment Failure",
    "Neutropenia"
  ],
  "friendlyJournalTitle": [],
  "isSponsored": null,
  "isEditorsPick": null,
  "authorId": null,
  "customMetaGroup": null,
  "relatedArticlesInfo": null
}